Abstract
In December 2017, the 15th annual Clinical Healthcare Academy Redefining Multiple Sclerosis (CHARMS) conference supported by Merck was held in London. Senior representatives from the multiple sclerosis (MS) nursing community sought to identify whether MS professionals across the UK consider the National Institute for Health and Care Excellence (NICE) quality standard in MS is currently being achieved and, if not, what were the barriers to service adherence. Issues identified included a lack of clinic capacity, poor or no access to neurophysiotherapy, and the absence of relapse or emergency clinic slots for patients in relapse. The significant burden of monitoring and administration of disease-modifying therapies (DMTs) was identified as contributing to the lack of capacity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
